TOBAM’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.12M | Sell |
36,844
-26,052
| -41% | -$1.5M | 0.52% | 63 |
|
|
2026
Q1 | $3.81M | Sell |
62,896
-31,028
| -33% | -$1.81M | 0.99% | 36 |
|
|
2025
Q4 | $5.07M | Sell |
93,924
-1,671
| -2% | -$80.4K | 1.24% | 28 |
|
|
2025
Q3 | $4.31M | Buy |
95,595
+14,107
| +17% | +$659K | 1.56% | 22 |
|
|
2025
Q2 | $3.77M | Buy |
81,488
+16,626
| +26% | +$816K | 1.47% | 27 |
|
|
2025
Q1 | $3.96M | Sell |
64,862
-51,420
| -44% | -$3M | 1.69% | 17 |
|
|
2024
Q4 | $6.58M | Sell |
116,282
-92,824
| -44% | -$5.19M | 2.01% | 9 |
|
|
2024
Q3 | $10.8M | Sell |
209,106
-9,203
| -4% | -$432K | 1.97% | 14 |
|
|
2024
Q2 | $9.07M | Sell |
218,309
-143,411
| -40% | -$6.42M | 1.42% | 23 |
|
|
2024
Q1 | $19.6M | Sell |
361,720
-170,184
| -32% | -$8.67M | 1.76% | 24 |
|
|
2023
Q4 | $27.3M | Sell |
531,904
-44,446
| -8% | -$2.33M | 2.39% | 15 |
|
|
2023
Q3 | $33.5M | Buy |
576,350
+6,437
| +1% | +$394K | 2.68% | 7 |
|
|
2023
Q2 | $36.4M | Sell |
569,913
-19,661
| -3% | -$1.32M | 2.75% | 9 |
|
|
2023
Q1 | $40.9M | Buy |
589,574
+298,474
| +103% | +$21.1M | 2.69% | 6 |
|
|
2022
Q4 | $20.9M | Buy |
291,100
+160,303
| +123% | +$12.1M | 1.39% | 28 |
|
|
2022
Q3 | $9.3M | Buy |
130,797
+113,765
| +668% | +$8.25M | 0.65% | 50 |
|
|
2022
Q2 | $1.31M | Buy |
17,032
+6,077
| +55% | +$463K | 0.08% | 116 |
|
|
2022
Q1 | $800K | Buy |
10,955
+3,821
| +54% | +$257K | 0.04% | 152 |
|
|
2021
Q4 | $445K | Hold |
7,134
| – | – | 0.02% | 150 |
|
|
2021
Q3 | $422K | Hold |
7,134
| – | – | 0.02% | 151 |
|
|
2021
Q2 | $477K | Sell |
7,134
-594
| -8% | -$38.7K | 0.02% | 151 |
|
|
2021
Q1 | $488K | Hold |
7,728
| – | – | 0.02% | 142 |
|
|
2020
Q4 | $479K | Sell |
7,728
-60,764
| -89% | -$3.74M | 0.02% | 145 |
|
|
2020
Q3 | $4.13M | Buy |
68,492
+2,604
| +4% | +$157K | 0.21% | 87 |
|
|
2020
Q2 | $3.87M | Sell |
65,888
-4,094
| -6% | -$245K | 0.25% | 74 |
|
|
2020
Q1 | $3.9M | Sell |
69,982
-69,427
| -50% | -$4.24M | 0.31% | 69 |
|
|
2019
Q4 | $8.95M | Sell |
139,409
-74,000
| -35% | -$4.24M | 0.55% | 58 |
|
|
2019
Q3 | $10.8M | Buy |
213,409
+13,414
| +7% | +$630K | 0.7% | 51 |
|
|
2019
Q2 | $9.07M | Sell |
199,995
-91,319
| -31% | -$4.25M | 0.5% | 60 |
|
|
2019
Q1 | $13.9M | Sell |
291,314
-284,791
| -49% | -$14.2M | 0.7% | 48 |
|
|
2018
Q4 | $29.9M | Sell |
576,105
-289,031
| -33% | -$15.5M | 1.44% | 24 |
|
|
2018
Q3 | $53.7M | Buy |
865,136
+14,186
| +2% | +$842K | 2.29% | 10 |
|
|
2018
Q2 | $47.1M | Buy |
850,950
+22,787
| +3% | +$1.23M | 1.94% | 12 |
|
|
2018
Q1 | $52.4M | Sell |
828,163
-105,882
| -11% | -$6.81M | 2.15% | 8 |
|
|
2017
Q4 | $57.2M | Sell |
934,045
-179,634
| -16% | -$11.2M | 2.48% | 5 |
|
|
2017
Q3 | $71M | Buy |
1,113,679
+17,590
| +2% | +$1.03M | 2.68% | 4 |
|
|
2017
Q2 | $61.1M | Buy |
1,096,089
+302,375
| +38% | +$16.5M | 2.28% | 10 |
|
|
2017
Q1 | $43.2M | Buy |
793,714
+440,170
| +125% | +$24.1M | 1.67% | 23 |
|
|
2016
Q4 | $20.7M | Buy |
+353,544
| New | +$19.3M | 0.84% | 45 |
|
|
2015
Q4 | – | Sell |
-187,916
| Closed | -$11.1M | – | 112 |
|
|
2015
Q3 | $11.1M | Sell |
187,916
-224,726
| -54% | -$14.3M | 0.43% | 55 |
|
|
2015
Q2 | $27.5M | Buy |
412,642
+367,519
| +814% | +$24.2M | 1% | 37 |
|
|
2015
Q1 | $2.91M | Buy |
+45,123
| New | +$2.82M | 0.09% | 103 |
|
Other funds holding BMY
TOBAM's BMY Position: Q2 2026 in Review
TOBAM reduced its Bristol-Myers Squibb (BMY) stake by 41% in Q2 2026, selling an estimated $1.5M and leaving 36,844 shares worth $2.12M. The position accounts for 0.52% of the portfolio, ranked #63.
TOBAM first reported a position in BMY in Q1 2015 and has held it in 42 quarters since. The position peaked at $71M in Q3 2017. 2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- TOBAM held 36,844 shares of Bristol-Myers Squibb worth $2.12M as of Q2 2026.
- TOBAM sold 26,052 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.5M.
- Bristol-Myers Squibb made up 0.52% of TOBAM's portfolio in Q2 2026, its #63 holding.
- TOBAM first reported a position in Bristol-Myers Squibb in Q1 2015 and has held it in 42 quarters since.
- TOBAM's Bristol-Myers Squibb position peaked at $71M in Q3 2017.
- 2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on TOBAM's 13F filing for Q2 2026, filed 31 Jul 2026.